Portfolio

SilvermanALS Therapy

Professor Richard Silverman (Weinberg College of Arts and Sciences), the world-renowned chemist who developed the pharmaceutical now marketed as Lyrica, and Assistant Professor Hande Ozdinler (Feinberg School of Medicine), an expert on upper motor neuron biology, now stand behind the University’s latest potential game-changing ALS innovation. The promising early effort combines Ozdinler’s novel approach for visualizing motor neurons in the brain with Silverman’s compounds designed for the inhibition of protein aggregation (PC12 cells), one of the hallmarks of ALS. More recently, the compounds have been shown to stabilize corticospinal motor neurons, the degeneration of which causes ALS. | THERAPEUTICS

N.XT Milestones

  1. Compound Synthesis
  2. Animal Studies
  3. PK Studies
  4. Venture Formation
  5. Intellectual Property Licensing

Battery TechnologyBattery Technology

N.XT funding will support Professor Mark Hersams validation studies for full battery operation in low temperature environments. Prof. Hersam has developed graphene-based materials for advanced cathodes for lithium ion batteries that overcome many of the limitations of conventional technology, including enhanced performance at low temperatures, high power and rapid recharging, and improved cycling stability and safety. Their ability to test low temperature cell designs and to demonstrate scale-up of materials and processing will provide critical data to shape their commercialization strategy. | ENERGY

N.XT Milestones

  1. Product Development with performance optimization
  2. Scale-up in material production

Third Coast TherapeuticsSmall Molecule for Cancer Therapeutic

N.XT funding will support initial preclinical work for a recent Northwestern licensee, Third Coast Therapeutics, which was co-founded by Professor Karl Scheidt. Third Coast focuses on the prevention of metastasis, thereby potentially improving established and emerging treatments for various cancers.  With the N.XT investment, Third Coast will focus on API production and toxicity studies of lead compound 3crx98, a small molecule that allosterically binds to the co-Chaperone Complex that is essential for cell homeostasis. The company has already secured significant IND funding from the DoD.  | THERAPEUTICS

N.XT Milestones

  1. Compound synthesis
  2. Toxicity study

Preora DiagnosticsCellular Aerosolization for Diagnostics

Professor Vadim Backman‘s startup, Preora Diagnostics, will utilize their N.XT investment to develop a beta prototype for an instrument that produces a novel aerosolization technique for cell plating analysis. This instrument will produce an impeccably uniform monolayer of high cells for improved cytological analysis in general and cancer diagnosis in particular.   | DIAGNOSTICS

N.XT Milestones

  1. Market research
  2. Beta prototype engineering and development
  3. Beta software development
  4. Clinical validation test